TLF、FOLFOX6与XELOX方案治疗进展期胃癌的成本-效果分析

目的:评价TLF、FOLFOX6与XELOX治疗进展期胃癌的成本效果。方法:收集中山大学附属肿瘤医院2004～2008年109例数据分为3组(TLF组50例,FOLFOX6组35例,XELOX组24例)。比较3组疗效,运用成本-效果分析法进行分析。结果:成本为医疗总费用时,TLF、FOLFOX6、XELOX的成本-效果比分别为167064.38、174876.61、164132.57,TLF、XELOX的增量成本-效果比分别为125960.22、146348.26;成本为总西药费时,TLF、FOLFOX6、XELOX的成本-效果比分别为125203.00、130233.67、135163.27,TLF、XELOX的增量成本-效果比分别为98734.07、143323.11。结论:成本为医疗总费用时,XELOX为最佳方案;成本为总西药费时,TLF为最合理方案。经济许可情况下,XELOX仍为最佳方案。

Cost-Effectiveness Analysis of TLF,FOLFOX6 and XELOX Therapeutic Schemes for Advanced Gastric Cancer

OBJECTIVE ：To evaluate cost-effectiveness of TLF,FOLFOX6 and XELOX in the treatment of advanced gastric cancer（AGC）. METHODS：109 cases of AGC collected from Tumor Hospital during 2004～2008 were divided into three groups, i.e. TLF group（n=50）;FOLFOX6 group（n=35）,XELOX group（n=24）. The curative effects and cost-effectiveness of three groups were analyzed. RESULTS：C/E ratios of three groups were 167 064.38,174 876.61,164 132.57 respectively when cost was equal to total medical cost. The incremental cost-effectiveness ratios of TLF and XELOX group were 125 960.22,146 348.26. The C/E ratios of three groups were 125 203.00,130 233.67,135 163.27 respectively when cost was equal to cost of western medicine. The incremental cost-effectiveness ratios of TLF and XELOX group were 98 734.07,143 323.11. CONCLUSION：When the cost is total medical cost,XELOX regimen is the best therapy for AGC;when the cost is the cost of western medicine,TLF regimen is optimum;XELOX regimen is still the best option under feasible economic condition.